Clinical Trials
3 trialsNCT04023071 2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT02670317 2017-03-20
FIL-GALILEO
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated